Compare Stocks: REVB, CTXR, CALC, and ADIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.09 +3.8%	$4.36	$1.31 ▼ $10.75	$13.37M	1.38	216,720 shs	24,846 shs
CALC CalciMedica	$1.95 -1.5%	$3.31	$1.87 ▼ $36.00	$13.33M	0.83	199,448 shs	65,143 shs
CTXR Citius Pharmaceuticals	$0.59 +0.7%	$0.59	$0.47 ▼ $2.19	$16.06M	1	599,773 shs	52,698 shs
REVB Revelation Biosciences	$0.98 -1.4%	$1.06	$0.88 ▼ $7.60	$3.90M	-0.14	264,575 shs	4,118 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-31.18%	+23.12%	+71.93%	-44.00%
CALC CalciMedica	0.00%	-8.76%	-41.34%	-54.48%	-87.51%
CTXR Citius Pharmaceuticals	0.00%	-1.14%	-23.11%	+7.59%	-51.98%
REVB Revelation Biosciences	0.00%	-1.55%	-6.38%	+0.13%	-87.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$5.09 +3.8%	$4.36	$1.31 ▼ $10.75	$13.37M	1.38	216,720 shs	24,846 shs
CALC CalciMedica	$1.95 -1.5%	$3.31	$1.87 ▼ $36.00	$13.33M	0.83	199,448 shs	65,143 shs
CTXR Citius Pharmaceuticals	$0.59 +0.7%	$0.59	$0.47 ▼ $2.19	$16.06M	1	599,773 shs	52,698 shs
REVB Revelation Biosciences	$0.98 -1.4%	$1.06	$0.88 ▼ $7.60	$3.90M	-0.14	264,575 shs	4,118 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-31.18%	+23.12%	+71.93%	-44.00%
CALC CalciMedica	0.00%	-8.76%	-41.34%	-54.48%	-87.51%
CTXR Citius Pharmaceuticals	0.00%	-1.14%	-23.11%	+7.59%	-51.98%
REVB Revelation Biosciences	0.00%	-1.55%	-6.38%	+0.13%	-87.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.40	Hold	$15.63	213.38% Upside
CALC CalciMedica	2.20	Hold	$50.00	2,418.89% Upside
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	756.16% Upside
REVB Revelation Biosciences	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest REVB, CTXR, CALC, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/11/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$4.75 per share	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$1.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	11/18/2026 (Estimated)
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
REVB Revelation Biosciences	-$8.91M	-$12.31	N/A	N/A	N/A	N/A	-100.19%	-82.72%	11/5/2026 (Estimated)

Latest REVB, CTXR, CALC, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A
8/6/2026	Q2 2026	REVB Revelation Biosciences	-$0.8750	-$0.87	+$0.0050	-$0.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
CALC CalciMedica	1.67	5.58	5.58
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
REVB Revelation Biosciences	N/A	6.22	6.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
CALC CalciMedica	N/A
CTXR Citius Pharmaceuticals	16.88%
REVB Revelation Biosciences	12.80%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	8.00%
CALC CalciMedica	28.25%
CTXR Citius Pharmaceuticals	4.99%
REVB Revelation Biosciences	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	2.63 million	2.42 million	No Data
CALC CalciMedica	30	6.83 million	4.90 million	No Data
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
REVB Revelation Biosciences	10	3.98 million	3.79 million	Not Optionable

REVB, CTXR, CALC, and ADIL Headlines

Recent News About These Companies

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

August 19, 2026 | finance.yahoo.com

REVB approaching a critical inflection point

August 7, 2026 | msn.com

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

August 6, 2026 | accessnewswire.comA

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

August 3, 2026 | accessnewswire.comA

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 21, 2026 | accessnewswire.comA

Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026 | finanznachrichten.de

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026 | accessnewswire.comA

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

June 1, 2026 | accessnewswire.comA

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

May 11, 2026 | accessnewswire.comA

REVB Poised for Big Year

May 8, 2026 | finance.yahoo.com

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

May 7, 2026 | accessnewswire.comA

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

April 6, 2026 | accessnewswire.comA

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

March 30, 2026 | oklahoman.comO

Revelation Biosciences (REVB) price target decreased by 37.65% to 54.06

March 28, 2026 | msn.com

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 24, 2026 | accessnewswire.comA

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 19, 2026 | accessnewswire.comA

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

February 26, 2026 | accessnewswire.comA

Revelation Biosciences (REVB) price target increased by 300.00% to 86.70

February 4, 2026 | msn.com

REVB Comes to Agreement with FDA

January 29, 2026 | finance.yahoo.com

REVB stock drops 10% after company announces third reverse split in a year

January 26, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, CTXR, CALC, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$5.08 +0.19 (+3.78%)

As of 11:52 AM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

CalciMedica NASDAQ:CALC

$1.95 -0.03 (-1.46%)

As of 11:52 AM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Citius Pharmaceuticals NASDAQ:CTXR

$0.58 +0.00 (+0.69%)

As of 11:49 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Revelation Biosciences NASDAQ:REVB

$0.98 -0.01 (-1.35%)

As of 11:48 AM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REVB, CTXR, CALC, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REVB, CTXR, CALC, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REVB, CTXR, CALC, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, CTXR, CALC, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

CalciMedica NASDAQ:CALC

Citius Pharmaceuticals NASDAQ:CTXR

Revelation Biosciences NASDAQ:REVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REVB, CTXR, CALC, and ADIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REVB, CTXR, CALC, and ADIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REVB, CTXR, CALC, and ADIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REVB, CTXR, CALC, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

CalciMedica NASDAQ:CALC

Citius Pharmaceuticals NASDAQ:CTXR

Revelation Biosciences NASDAQ:REVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools